.jpg)
.png)
The “response to retention” model of atherosclerosis holds up as the present and best narrative explanation for the initiation and propagation of atherosclerotic cardiovascular disease (ASCVD).(1) As you know, this model posits that the passage of apolipoprotein B (apoB)-containing lipoproteins (LP) triggers the initiation of the atheroma.
Article By:
Clinical Associate Professor of Medicine
University of Pennsylvania
Internal Medicine and Preventive Cardiology
University of Pennsylvania Health System
Philadelphia, PA
Diplomate, American Board of Clinical Lipidology
I am honored to have the opportunity to work with you all in promoting education, service and quality improvement efforts in clinical lipidology and preventive cardiology as this year’s President of the Pacific Lipid Association.
Article By:
President, Pacific Lipid Association Professor and Director, Heart Disease Prevention Program
Division of Cardiology, University of California
Irvine, CA
“Knowing is not enough; we must apply. Willing is not enough; we must do.” This remark by Goethe introduces readers to the rationale for the Institute of Medicine of the National Academies Committee on Standards for Developing Trustworthy Clinical Practice Guidelines: Guidelines We Can Trust 2011.
Article By:
President, National Lipid Association Director, Division of Cardiology
Advocate Lutheran General Hospital
Co-Director, Cardiology Service Line
Advocate Medical Group
Clinical Associate Professor
Loyola Stritch School of Medicine
Park Ridge, IL
Diplomate, American Board of Clinical Lipidology
Editor, LipidSpin
Clinical Associate Professor of Medicine
University of Pennsylvania
Internal Medicine and Preventive Cardiology
University of Pennsylvania Health System
Philadelphia, PA
Diplomate, American Board of Clinical Lipidology
Editor, LipidSpin
Medical Director, Lipid Clinic and Physician Advisor
Ascension Wisconsin All Saints
Racine, WI
Diplomate, American Board of Clinical Lipidology
Sanofi and Regeneron announced on Monday, Feb. 11 alirocumab will be made available at a reduced list price to help lower patient out-of-pocket costs and improve access.
The NLA has released its clinician tear sheet on the 2018 Guideline on the Management of Blood Cholesterol.
The tear sheet is an important resource for physicians to quickly and easily reference key points from the 2018 Guideline at a glance. It can be printed or shared electronically for reference at physician practices in addition to being shared among colleagues.
Check back later for more NLA clinical resources and tools related to the 2018 Guideline.
 |
 |
Nov. 10, 2018
CHICAGO ‒ The REDUCE-IT cardiovascular outcomes trial results, announced today at the American Heart Association Scientific Sessions in Chicago, met its primary composite endpoint and revealed a reduction in major adverse cardiovascular events (MACE) of 25%.
Download the manuscript online now.
Nov. 10, 2018
NLA among 12 organizations to co-author, endorse key document for reducing risk of atherosclerotic cardiovascular disease
Oct. 25, 2018
Amgen announced on Wednesday, Oct. 24 it is making evolocumab available at a reduced list price in an effort to improve affordability and access for patients.
The announcement represents positive news for patients at risk for cardiovascular events.
Key outcomes from Amgen’s FOURIER trial, revealed in March 2017, revealed evolocumab significantly reduced the risk of cardiovascular events and were supported by long-term safety data.
The Foundation of the NLA has seen great progress over the past several months. At our summer board of directors meeting, the board voted unanimously to add seven new at-large board members: Joyce L. Ross, MSN, CRNP, CLS, FNLA from the University of Pennsylvania Health System, Lori A. Alexander, MSHS, RD, CCRC, CLS, FNLA from the Jacksonville Center for Clinical Research, Robert A. Wild, MD, MPH, PhD, FNLA, FASPC from Oklahoma University Health Sciences Center, Don P.
Article By:
President, Foundation of the National Lipid Association
Associate Professor of Medicine
Washington University School of Medicine
St. Louis, MO
Diplomate, American Board of Clinical Lipidology